Intrabony Periodontal Defect
Conditions
Brief summary
Will the addition of vitamin A (Retinol) to PRF add more periodontal regenerative value in the treatment of intra-bony defects compared to PRF alone, clinically?
Detailed description
Vitamin A has been extensively studied for its role in bone health. Vitamin A can be consumed in two forms, i.e., preformed retinol and pro-vitamin A. Preformed retinol is often found in food originated from animals, such as dairy, liver and eggs. Provitamin A, such as alpha (α)-carotene, beta (β)-carotene orβ-cryptoxanthin, are commonly found in plant-based food, such as fruits and vegetables (Toti et al., 2018). At certain concentrations, it has been proven to enhance the pluripotency of periodontal cells for regeneration (Fawzy El-Sayed, Hein and Dörfer, 2019). Yet, to the best of our knowledge no clinical trials have evaluated the effect of Vitamin A added to PRF in the regeneration of intra-bony defects. This study is to fill the gap of knowledge.
Interventions
BIOLOGICALPlatelet Rich Fibrin (PRF)
Platelet rich fibrin (PRF) in treatment of intrabony defects using Modified Minimally invasive surgical technique (M-MIST)
BIOLOGICALPlatelet Rich Fibrin (PRF) and Retinol
Platelet rich fibrin (PRF) mixed with Retinol in treatment of intrabony defects using Modified Minimally invasive surgical technique (M-MIST)
Sponsors
Cairo University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Stage III periodontitis patient (Papapanou et al., 2018) with 3 walled or 2 walled intra-bony defects. * Non-smokers * No pregnancy * Medically free * Presence of intra-bony defect of three or two walls (as predominant component) with a radiographic intra-bony component of ≥3 mm; * Presence of ≥2 mm of keratinized gingiva at the tooth with the defect. * Willingness to optimal compliance with the study procedures
Exclusion criteria
* Uncontrolled systemic or local infection in the tissue of interest, * History or clinical evidence or positive tests for Human Immunodeficiency Virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV). * History of chronic autoimmune disease * Participation in an intervention trial in the same quadrant in the previous two months. * Type III tooth mobility, vertical root fracture in the selected tooth. * Contraindications for periodontal surgery.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Radiographic linear defect depth | 6 Month | Measured as the depth of intra-osseous defect from the alveolar crest to the defect base (E et al., 2004) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical attachment level | 6 Month | clinical attachment level measured in mm. using williams graduated probe(SP, 1967) |
| Probing pocket depth | 6 Month | Measuring probing depth in mm using William's graduated Periodontal probe (SP, 1967) |
| Radiographic defect bone density | 6 MOnth | Bone density will be measured using Digital Radiographs using ImageJ software (B et al., 2019) |
Countries
Egypt
Contacts
Primary ContactAbdallah H. Mostafa, M.Sc.
Outcome results
None listed